Clinical Research Directory

Inclusion Criteria for T2D Cohort: * Age 18 years old or older * A clinical diagnosis of T2D ≥ 1 year * Baseline HbA1c ≥ 7.5% * ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date * ≥ one body weight value up to 6 months (+ 90 days) prior to index date * Initiated injectable semaglutide or switched from injectable semaglutide to tirzepatide between January 1, 2022, and December 31, 2025 * Use of injectable semaglutide for ≥ 3 months for both the control and switch cohort * If using real-time continuous glucose monitoring (rtCGM) or intermittently scanned continuous glucose monitoring (isCGM), CGM use for ≥ 3 months * Seen by an LMC endocrinologist in the last 18 months as of the query date * Informed data consent for their medical record data to be used for research purposes Inclusion Criteria for Obesity (non-diabetes) Cohort: * Age 18 years old or older * BMI ≥ 30 kg/m2 * Baseline HbA1c \< 6.5% * ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date * ≥ one body weight value up to 6 months (+ 90 days) prior to index date * Initiated injectable semaglutide and switched from injectable semaglutide to tirzepatide between January 1, 2022, and December 31, 2025 * Use of injectable semaglutide for ≥ 3 months * Seen by an LMC endocrinologist in the last 18 months as of the query date * Informed data consent for their medical record data to be used for research purposes Exclusion Criteria: * Clinical diagnosis of type 1 diabetes or latent autoimmune diabetes in adults * Prior use of tirzepatide * Were pregnant at the time of semaglutide initiation or semaglutide-to-tirzepatide switch or became pregnant during follow-up period * Bariatric surgery